CervoMed (CRVO) Gross Margin (2011 - 2013)

CervoMed (CRVO) posted Gross Margin of 100.0% for Q2 2013, up 0.6% sequentially from 99.41% in Q3 2012, and up 59.0% YoY from 62.89% in Q2 2012.

CervoMed (CRVO) Gross Margin (2011 - 2013) Analysis & Trends

CervoMed has reported Gross Margin for 3 years, with the latest figure at 100.0% in Q2 2013.

Quarterly Gross Margin rose 59.0% year-over-year to 100.0% in Q2 2013, while the trailing twelve-month figure through Mar 2014 was 100.0% (up 59.0% YoY) and the FY2012 annual result came in at 37.04%, up 34172.0% from the prior year.
Gross Margin improved to 100.0% in Q2 2013 per CRVO's latest filing, from 99.41% in the prior quarter.
Over five years, Gross Margin peaked at 100.0% in Q2 2013 and troughed at 541.57% in Q4 2011.
A 3-year average of 47.9% and a median of 48.98% in 2011 frame the typical range for Gross Margin.
The sharpest annual moves came in 2012 and 2013: Gross Margin surged 10085 bps in 2012, then jumped 59 bps in 2013.
Over 3 years, Gross Margin stood at 541.57% in 2011, then soared by 118 bps to 99.41% in 2012, then advanced by 1 bps to 100.0% in 2013.
According to Business Quant data, Gross Margin over the past three periods registered 100.0%, 99.41%, and 99.41% for Q2 2013, Q3 2012, and Q2 2012 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	138.79 Bn	130.93 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	85.99 Bn	78.00 Bn	3.93 Bn	91.59%
3	Argenx Se	65.26 Bn	60.07 Bn	1.37 Bn	90.43%
4	Moderna	56.04 Bn	50.91 Bn	52.00 Mn	35.86%
5	BeOne Medicines	42.05 Bn	36.95 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	31.71 Bn	28.40 Bn	992.69 Mn	76.90%
7	BioNTech SE	27.66 Bn	9.26 Bn	668.28 Mn	63.27%
8	Insmed	27.50 Bn	26.33 Bn	358.27 Mn	84.20%
9	Royalty Pharma	27.35 Bn	26.52 Bn	-	-
10	CervoMed	26.64 Mn	26.64 Mn	-	-

Download Data